https://doi.org/10.4081/uij.2004.5

SINGLE-DOSE PRULIFLOXACIN VERSUS SINGLE-DOSE PEFLOXACIN IN THE TREATMENT OF ACUTE UNCOMPLICATED URINARY TRACT INFECTION IN WOMEN

Vol. 18 No. 3 (2004)
Submitted: 18 June 2010
Accepted: 18 June 2010
Published: 1 July 2010
Prulifloxacin, pefloxacin, single-dose, acute uncomplicated UTIs
Abstract Views: 514
PDF: 410
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M. CERVIGNI
rd.dionisio@angelini.it
SAN CARLO HOSPITAL, UROGYNAECOLOGICAL UNIT - ROME,, Italy.
G. ORTICELLI
A.C.R.A.F. S.P.A., MEDICAL DEPARTMENT - ROME,, Italy.
M. BOLOGNA
SAN CARLO HOSPITAL, UROGYNAECOLOGICAL UNIT - ROME,, Italy.
F. NATALE
SAN CARLO HOSPITAL, UROGYNAECOLOGICAL UNIT - ROME,, Italy.
E. SALVATORI
A.C.R.A.F. S.P.A., MEDICAL DEPARTMENT - ROME,, Italy.
G. DI LORETO
A.C.R.A.F. S.P.A., MEDICAL DEPARTMENT - ROME,, Italy.
P. DIONISIO
A.C.R.A.F. S.P.A., MEDICAL DEPARTMENT - ROME,, Italy.
The aim of the study was to compare the efficacy and safety of singledose prulifloxacin vs. single-dose pefloxacin in the treatment of patients with acute uncomplicated urinary tract infections. Two hundred and thirty-one female out-patients were considered microbiologically evaluable and randomly treated with 600 mg prulifloxacin (116 patients) or 800 mg pefloxacin (115 patients). The most commonly isolated uropathogen at baseline was Escherichia coli (71.4%), followed by Proteus mirabilis (10.8%) and Klebsiella pneumoniae (7.8%). Five-seven days posttreatment, the eradication rate was 97.4% and 92.2% in the prulifloxacin and pefloxacin group, respectively. The one-tailed 95% confidence interval analysis showed the equivalence of treatments. Four weeks from treatment no relapses, reinfections or superinfections were observed. The clinical success rates were 92.2% in the prulifloxacin and 84.3% pefloxacin groups. The safety profile was very good with both drugs. The results of the study make it possible to consider prulifloxacin a possible therapeutic option in patients with acute uncomplicated UTIs.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

CERVIGNI, M., ORTICELLI, G., BOLOGNA, M., NATALE, F., SALVATORI, E., DI LORETO, G., & DIONISIO, P. (2010). SINGLE-DOSE PRULIFLOXACIN VERSUS SINGLE-DOSE PEFLOXACIN IN THE TREATMENT OF ACUTE UNCOMPLICATED URINARY TRACT INFECTION IN WOMEN. Urogynaecologia, 18(3), 5–13. https://doi.org/10.4081/uij.2004.5

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

An Open Access Publication is one that meets the following two conditions:

  1. the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.
  2. a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.